Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Autolus Therapeutics and NewAmsterdam Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autolus Therapeutics | $75.39 million | 6.28 | -$287.53 million | ($1.06) | -1.68 |
| NewAmsterdam Pharma | $22.50 million | 123.26 | -$203.82 million | ($2.16) | -10.74 |
NewAmsterdam Pharma has lower revenue, but higher earnings than Autolus Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Autolus Therapeutics and NewAmsterdam Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
| NewAmsterdam Pharma | 1 | 1 | 10 | 1 | 2.85 |
Autolus Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 461.80%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 114.34%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than NewAmsterdam Pharma.
Profitability
This table compares Autolus Therapeutics and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| NewAmsterdam Pharma | -3,644.21% | -34.81% | -31.50% |
Summary
Autolus Therapeutics beats NewAmsterdam Pharma on 9 of the 15 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
